Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

Official Title

A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Details

This study will consist of 4 study periods of up to 50 months in total, consisting of:

Screening Period - A maximum screening duration of 4 weeks.

Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months.

End of Treatment Visit - A minimum of 4 weeks post last treatment for both arms.

Follow-Up Period - Up to 24 months.

A total of approximately 280 patients will be randomized in a 1:1 ratio to receive either eflornithine + lomustine or lomustine alone.

Keywords

Anaplastic Astrocytoma Recurrent Anaplastic Astrocytoma Grade 3 Glioma Glioma Eflornithine Brain Cancer Brain Tumor Neuro-oncology Progressive Anaplastic Astrocytoma Progressive Glioma Recurrent Glioma Malignant Glioma Progressive Brain Tumor Recurrent Brain Tumor Astrocytoma Lomustine

Eligibility

You can join if…

Open to people ages 18 years and up

Patients must meet all of the following inclusion criteria to be eligible for participation in this study:

  • Surgical or biopsy-proven diagnosis of WHO grade 3 AA.
  • Unequivocal evidence of first AA tumor progression or recurrence ≤ 3 months prior to randomization based on MRI criteria for tumor progression using enlarging Gd-contrast enhancement and/or T2 hypersensitivity (Appendix 4). Patients with non-measurable Gd contrast enhancing tumors will only be eligible if there is no necrosis seen on MRI and/or histopathological confirmation of AA per standard of care procedures is obtained within 4 weeks prior to randomization.
  • First tumor progression or recurrence following surgical resection or biopsy, if resection is not feasible, EBRT and temozolomide chemotherapy.
  • Completion of EBRT ≥ 6 months prior to randomization.
  • A patient whose AA tumor has progressed or recurred and has had another surgical resection prior to randomization will be eligible if a) pathology review confirms AA,b) post-surgical MRI demonstrates measurable tumor on T2/FLAIR, and c) MRI performed after surgery is within 4 weeks prior to randomization.
  • Karnofsky Performance Status (KPS) score of > 70.

You CAN'T join if...

Patients who meet any of the following exclusion criteria are not eligible for study participation:

  • MRI defining progression is consistent with a diagnosis of glioblastoma or radiation necrosis.
  • Patients who are considered to be refractory to EBRT and temozolomide but who have not progressed.
  • Prior systemic therapy for recurrence of AA.
  • Presence of extracranial or leptomeningeal disease.
  • Prior lomustine use.
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.
  • Pregnant or breastfeeding.

Locations

  • University of California San Francisco Medical Center accepting new patients
    San Francisco, California, 94143, United States
  • Kaiser Permanente Center accepting new patients
    Redwood City, California, 94063, United States
  • Kaiser Permanente accepting new patients
    Sacramento, California, 95825, United States
  • Kaiser Permanente accepting new patients
    Los Angeles, California, 90027, United States
  • John Wayne Cancer Institute accepting new patients
    Santa Monica, California, 90404, United States
  • University of Southern California Norris Comprehensive Cancer Center accepting new patients
    Los Angeles, California, 90033, United States
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles, California, 90095, United States
  • University of California Irvine Medical Center accepting new patients
    Orange, California, 92868, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Orbus Therapeutics, Inc.
ID
NCT02796261
Phase
Phase 3
Lead Scientist
Study Type
Interventional
Last Updated
August 21, 2017
I’m interested in this study!